期刊文献+

Redox-active nanoparticles for inflammatory bowel disease 被引量:2

原文传递
导出
摘要 Homeostasis of gut microbiota is extremely essential for maintaining nutrient metabolism and regulating immunological function.The increasing evidence suggests that inflammatory bowel disease(IBD)is strongly associated with dysregulation of gut microbiota.During activated inflammation,excessive reactive oxygen species(ROS)and reactive nitrogen species(RNS)produced by inflammatory cells play a detrimental role in regulating IBD and gut microbiota.ROS/RNS cause damage to the surrounding tissues,including nutrient absorption disorders,intestinal dysmotility and barrier dysfunction.Meanwhile,ROS/RNS provide terminal electron receptors for anaerobic respiration and support the bloom of facultative anaerobes,eventually causing gut microbiota dysbiosis.Redox-active nanoparticles(NPs)with catalytic properties or enzyme-like activities can effectively scavenge ROS/RNS,and selectively target inflamed sites via ultrasmall size-mediated enhanced permeation and retention(EPR)effect,showing great potential to regulate IBD and maintain the homeostasis of gut microbiota.In addition,the widespread application of NPs in commercial products 1 has increased their accumulation in healthy organisms,and the biological effects on normal microbiota resulting from long-term exposure of NPs to gastrointestinal tract also need attention.
出处 《Nano Research》 SCIE EI CSCD 2021年第8期2535-2557,共23页 纳米研究(英文版)
基金 supported by the National Natural Science Foundation of China(Nos.91859101,81971744,U1932107,and 81471786) the National Natural Science Foundation of Tianjin(No.19JCZDJC34000) the Innovation Foundation of Tianjin University.
作者简介 Qinjuan Ren,contributed equally to this work;Si Sun,contributed equally to this work;Address correspondence:Xiao-Dong Zhang,xiaodongzhang@tju.edu.cn。
  • 相关文献

参考文献5

二级参考文献44

  • 1Szakacs, G.; Paterson, J. K.; Ludwig, J. A.; Booth-Genthe, C.; Gottesman, M. M. Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov. 2006, 5, 219-234.
  • 2Kirkin, V.; Joos, S.; Zornig, M. The role of Bcl-2 family members in tumorigenesis. Biochim. Biophys. Acta-Mol. Cell Res. 2004, 1644,229-249.
  • 3Kruh, G. D. Introduction to resistance to anticancer agents. Oncogene 2003, 22, 7262-7264.
  • 4Calderwood, S. K.; Khaleque, M. A.; Sawyer, D. B.; Ciocca, D. R. Heat shock proteins in cancer: Chaperones of tumorigenesis. Trends Biochem. Sci. 2006,31, 164-172.
  • 5Duhem, C.; Ries, F.; Dicato, M. What does multidrug resistance (MDR) expression mean in the clinic. Oncologist 1996,1,151-158.
  • 6Krishna, R.; Mayer, L. D. Multidrug resistance (MDR) in cancer: Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur. J. Pharm. Sci. 2000,11,265-283.
  • 7Ferry, D. R.; Traunecker, H.; Kerr, D. J. Clinical trials of P-gJycoprotein reversal in solid tumours. Eur. J. Cancer 1996, 32A, 1070-1081.
  • 8Rowinsky, E. K.; Smith, L.; Wang, Y. M.; Chaturvedi, P.; Villalona, M.; Campbell, E.; Aylesworth, C.; Eckhardt, S. G.; Hammond, L.; Kraynak, M., et al. Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDRI and MRP. J. Clin. Oncol. 1998,16,2964-2976.
  • 9Jabr-Milane, L. S.; van Vlerken, L. E.; Yadav, S.; Amiji, M. M. Multi-functional nanocarriers to overcome tumor drug resistance. Cancer Treat Rev. 2008, 34, 592-602.
  • 10Moore, A.; Basilion, J. P.; Chiocca, E. A.; Weissleder, R. Measuring transferrin receptor gene expression by NMR imaging. Biochim. Biophys. Acta-Mol. Cell Res. 1998, 1402, 239-249.

共引文献34

同被引文献33

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部